by Frank Sorce | Aug 9, 2022 | Case Studies
IMPACT (now part of Syner-G BioPharma Group) has been providing Regulatory Affairs support to a mid-size pharmaceutical company since 2009. Even though this company has a Regulatory Affairs Department, their rapid growth over the years has made “in-sourcing” of help...
by Frank Sorce | Aug 9, 2022 | Case Studies
In 2013, the IMPACT (now part of Syner-G BioPharma Group) management team decided that the company needed to build a Regulatory Operations department to support their existing and future client base. The staff to manage and support this group was secured. Hosted...
by Frank Sorce | Jun 13, 2022 | Press Releases
RESEARCH TRIANGLE PARK, NC: 13 June 2022 Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). Mr. Kraus has...
by Frank Sorce | May 4, 2022 | Blog, Drug Development Consulting
May 4, 2022 | Nathaniel DiTommaso, MS, Regulatory Affairs Manager In May of 2014 and February of 2019, the FDA released final Guidance for Industry outlining the Agency’s policies and procedures regarding expedited development and review programs for new drugs and...
by Frank Sorce | Mar 2, 2022 | Press Releases
RESEARCH TRIANGLE PARK, NC: 01 March 2022 – In the second half of 2021, IMPACT’s (now Syner-G BioPharma Group’s) employees continued their generous efforts via the Making an IMPACT (MAI) community service initiative. We continued our charitable and community outreach...
